MBG Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Marinomed Biotech AG

Watchlist Manager

Watchlist

Price: 44.74 EUR -0.51%

Market Cap: €48B

	Marinomed Biotech AG F:MBG	AT
S	Slang Worldwide Inc F:84SA	CA
K	Kyushu Railway Co F:KRH	JP
D	Daiwa Securities Group Inc XMUN:DSE	JP
G	Gree Inc F:V3U	JP
	ROKMASTER Resources Corp F:1RR1	CA
C	Crinetics Pharmaceuticals Inc F:6Z4	US
	Avrupa Minerals Ltd F:8AMA	CA
P	Power Metal Resources PLC OTC:POWMF	UK
B	Bank of Jiujiang Co Ltd F:BJ8	CN

Profitability Summary

Marinomed Biotech AG's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

58%

Sustainable 3Y Average Gross Margin

22%

Gross Margin is Increasing

17% > 58%

Exceptional Operating Margin

112%

Negative 3Y Average Operating Margin

-51%

Operating Margin is Increasing

-46% > 112%

Exceptional Net Margin

44%

Negative 3Y Average Net Margin

-122%

Net Margin is Increasing

-52% > 44%

Negative Free Cash Flow Margin

-21%

Negative 3Y Average Free Cash Flow Margin

-54%

Free Cash Flow Margin is Increasing

-48% > -21%

Negative ROE

-41%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-18%

ROIC is Increasing

-44% > 174%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.